PMID- 23333798
OWN - NLM
STAT- MEDLINE
DCOM- 20130617
LR  - 20211021
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 333
IP  - 1
DP  - 2013 Jun 1
TI  - Wnt pathway contributes to the protection by bone marrow stromal cells of acute 
      lymphoblastic leukemia cells and is a potential therapeutic target.
PG  - 9-17
LID - S0304-3835(13)00037-2 [pii]
LID - 10.1016/j.canlet.2012.11.056 [doi]
AB  - Leukemia cells are protected by various components of their microenvironment, 
      including marrow stromal cells (MSCs). To understand the molecular mechanisms 
      underlying this protection, we cultured acute lymphoblastic leukemia (ALL) cells 
      with MSCs and studied the effect of the latter on the molecular profiling of ALL 
      cells at the mRNA and protein levels. Our results indicated that activated Wnt 
      signaling in ALL cells is involved in MSC-mediated drug resistance. Blocking the 
      Wnt pathway sensitized the leukemia cells to chemotherapy and improved overall 
      survival in a mouse model. Targeting the Wnt pathway may be an innovative 
      approach to the treatment of ALL.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Bone Marrow Transplant Center, First Affiliated Hospital, Medical 
      School of Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Mallampati, Saradhi
AU  - Mallampati S
FAU - Sun, Baohua
AU  - Sun B
FAU - Zhang, Jing
AU  - Zhang J
FAU - Kim, Sang-Bae
AU  - Kim SB
FAU - Lee, Ju-Seog
AU  - Lee JS
FAU - Gong, Yun
AU  - Gong Y
FAU - Cai, Zhen
AU  - Cai Z
FAU - Sun, Xiaoping
AU  - Sun X
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R03 AI079779/AI/NIAID NIH HHS/United States
GR  - CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130116
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (CTNNB1 protein, human)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (XAV939)
RN  - 0 (beta Catenin)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Cycle
MH  - Cytarabine/pharmacology
MH  - Gene Expression Regulation, Leukemic
MH  - Heterocyclic Compounds, 3-Ring/pharmacology
MH  - Humans
MH  - Mesenchymal Stem Cells/*physiology
MH  - Mice
MH  - Mice, SCID
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/pathology
MH  - Wnt Signaling Pathway/*physiology
MH  - beta Catenin/physiology
PMC - PMC3880833
MID - NIHMS530780
COIS- Authorship and Disclosures Y.Y., Y.G., Z.C., and X.S. initiated the study, 
      designed the experiments, and wrote the paper. Y.Y., S.M., B.S., J.Z., S.K., and 
      J.S.L. performed the experiments and statistical analyses. The authors have no 
      conflicts of interest to disclose.
EDAT- 2013/01/22 06:00
MHDA- 2013/06/19 06:00
PMCR- 2014/06/01
CRDT- 2013/01/22 06:00
PHST- 2012/08/05 00:00 [received]
PHST- 2012/11/11 00:00 [revised]
PHST- 2012/11/13 00:00 [accepted]
PHST- 2013/01/22 06:00 [entrez]
PHST- 2013/01/22 06:00 [pubmed]
PHST- 2013/06/19 06:00 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - S0304-3835(13)00037-2 [pii]
AID - 10.1016/j.canlet.2012.11.056 [doi]
PST - ppublish
SO  - Cancer Lett. 2013 Jun 1;333(1):9-17. doi: 10.1016/j.canlet.2012.11.056. Epub 2013 
      Jan 16.